Xilio Therapeutics announced initial monotherapy safety and anti-tumor activity data for XTX202, a tumor-activated, engineered, Beta-Gamma IL-2, in late line patients with advanced solid tumors. The treatment showed a 50% disease control rate at higher doses and 31% across all dose levels. Adverse events were primarily Grade 1-2 at doses up to 4 mg/kg. Two patients have been on the treatment for over a year, indicating good tolerance. Xilio plans to evaluate XTX202 in a Phase 2 trial in patients with advanced melanoma and renal cell carcinoma.